ISRCTN86885538 https://doi.org/10.1186/ISRCTN86885538

Taurolidine-citrate vs heparin as catheter lock solutions in paediatric patients

Submission date	Recruitment status	[_] Prospectively registered
07/12/2006	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
16/01/2007	Completed	[_] Results
Last Edited	**Condition category**	[_] Individual participant data
08/02/2011	Infections and Infestations	[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Uwe Querfeld

Contact details
Department of Pediatric Nephrology
Charité Universitätsmedizin Berlin
Berlin
Germany
13353

Additional identifiers

Protocol serial number
EA2/084/06

Study information

Scientific Title

Acronym
Taurolock study

Study objectives
Use of taurolidine-citrate for catheter locking leads to a significant reduction of bacterial growth and catheter-related infections in paediatric patients with implanted central venous catheters

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approval received by local ethics committee (Ethikkommission 2 am Campus Virchow Klinikum) on 29 September 2006 (ref: EA2/084/06).

Study design
Randomized prospective study in pediatric hospital with stratification for patients treated in renal/oncology/hematology departments

Primary study design
Interventional

Study type(s)
Not Specified

Health condition(s) or problem(s) studied
Catheter-related infections

Interventions
Taurolidine-citrate vs heparin as catheter lock solutions

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Bacterial growth/biofilm formation in removed catheters

Key secondary outcome(s))
Catheter-related infections, catheter occlusions

Completion date
31/12/2007

Eligibility

Key inclusion criteria
Paediatric patients with newly implanted central venous catheters

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Child

Sex
Not Specified

Key exclusion criteria
Bacteremia/sepsis ongoing; allergy against heparin or taurolidine

Date of first enrolment
01/01/2007

Date of final enrolment
31/12/2007

Locations

Countries of recruitment
Germany

Study participating centre
Department of Pediatric Nephrology
Berlin
Germany
13353

Sponsor information

Organisation
Tauropharm (Germany)

Funder(s)

Funder type
Industry

Funder Name
Tauropharm GmbH (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration